Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abilify Maintena
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Abilify Maintena is a long-acting injectable (LAI) formulation of aripiprazole, an atypical antipsychotic developed by Otsuka Pharmaceutical in collaboration with Lundbeck. It is designed as a sterile lyophilized powder that, when reconstituted, forms a suspension for intramuscular injection, typically administered once monthly (every 4 weeks). Aripiprazole's unique pharmacological profile involves partial agonism at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonism at serotonin 5-HT2A receptors. This "dopamine-serotonin system stabilizer" effect helps manage both positive and negative symptoms of schizophrenia while minimizing extrapyramidal side effects. Abilify Maintena is indicated for the maintenance treatment of schizophrenia in adults and as maintenance monotherapy for bipolar I disorder. The depot formulation provides sustained therapeutic plasma concentrations over approximately 30 days, significantly improving treatment adherence compared to daily oral medications.
- Brand names
- Abilify Maintena
- Other names
- aripiprazole intramuscular depotaripiprazole long-acting injectablearipiprazole depotaripiprazole prolonged-release suspension for injection
02
Targets
ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on Abilify Maintena.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abilify Maintena.